
Mustang Bio Inc (NASDAQ:MBIO) shares are trading sharply higher Monday afternoon. The company earlier saw a positive development as the FDA granted Orphan Drug Designation to its cell therapy candidate, MB-101. Here’s what investors need to know.
What To Know: This designation is for the treatment of aggressive brain cancers, including recurrent diffuse and anaplastic astrocytoma and glioblastoma.